Publications

Selected Publications

 

2017

 
Zhong Q, Guo T, Rechsteiner M, Rüschoff JH, Rupp NJ, Fankhauser C, Saba K, Mortezavi A, Poyet C, Hermanns T, Zhu, Y, Moch H, Aebersold R, Wild PJ. Image-based computational quantification and visualization of genetic alterations and tumour heterogeneity. A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients. Scientific Data 4, Article number: 170014

 
Zerhouni E, Prisacari B, Zhong Q, Wild P, Gabrani M. Heterogeneity characterization of immunohistochemistry stained tissue using convolutional autoencoder. Proc. SPIE 10140, Medical Imaging 2017: Digital Pathology.
 

Corrò C, Hejhal T, Poyet C, Sulser T, Hermanns T, Winder T, Prager G, Wild PJ, Frew I, Moch H, Rechsteiner M. Detecting circulating tumor DNA in renal cancer: An open challenge. Exp Mol Pathol. 2017 Feb 22;102(2):255-261.

 

Valtcheva N, Lang FM, Noske A, Samartzis EP, Schmidt AM, Bellini E, Fink D, Moch H, Rechsteiner M, Dedes KJ, Wild PJ. Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing – a case report. BMC Cancer. 2017 Jan 19;17(1):66. doi: 10.1186/s12885-017-3054-6.

 

2016

 

Velizheva NP, Rechsteiner MP, Wong CE, Zhong Q, Rössle M, Bode B, Moch H, Soltermann A, Wild PJ, Tischler V. Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
Cancer Cytopathol. 2016 Sep 16. doi: 10.1002/cncy.21771.

 

Noske A, Brandt S, Valtcheva N, Wagner U, Zhong Q, Bellini E, Fink D, Obermann EC, Moch H, Wild PJ. Detection of CCNE1/URI (19q12) amplification by in situ hybridisation is common in high grade and type II endometrial cancer.
Oncotarget. 2016 Aug 25. doi: 10.18632/oncotarget.11605

 

Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato AC, Tschopp P, Gu L, Corsinotti A, Zhong Q, Fankhauser C, Fritz C, Poyet C, Wagner U, Guo T, Aebersold R, Garraway LA, Wild PJ, Theurillat JP, Brown M. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
Cancer Cell 6, 24146; doi: 10.1016/j.ccell.2016.04.012 (2016).

 

Zhong Q, Rüschoff JH, Guo T, Gabrani M, Schüffler PJ, Rechsteiner M, Liu Y, Fuchs TJ, Rupp NJ, Fankhauser C, Buhmann JM, Perner S, Poyet C, Blattner M, Soldini D, Moch H, Rubin MA, Noske A, Rüschoff J, Haffner MC, Jochum W, Wild PJ. Image-based computational quantification and visualization of genetic
alterations and tumour heterogeneity.
Sci Rep. 6, 24146; doi: 10.1038/srep24146 (2016).

 

Erwan Zerhouni, Bogdan Prisacari, Qing Zhong, Peter Wild, Maria Gabrani. Deciphering protein signatures using color, morphological, and topological analysis of immunohistochemically stained human tissues.
Proc. SPIE 9791, Medical Imaging: Digital Pathology, doi:10.1117/12.2218016 (2006).

 

Rupp Niels J, Schuffler Peter J, Zhong Qing, Falkner Florian, Rechsteiner Markus, Ruschoff Jan H, Fankhauser Christian, Drach Matthias, Largo Remo, Tremp Mathias, Poyet Cedric, Sulser Tullio, Kristiansen Glen, Moch Holger, Buhmann Joachim, Muntener Michael, Wild Peter J. Oxygen supply maps for hypoxic microenvironment visualization in prostate cancer.
J Pathol Inform. doi: 10.4103/2153-3539.175376 (2016).

 

Erwan Zerhouni, Bogdan Prisacari, Qing Zhong, Peter Wild, Maria Gabrani (2016) A computational framework for disease grading using protein signatures.
IEEE ISBI. (Accepted)

 

2015

 

Poyet C, Hermanns T, Zhong Q, Drescher E, Eberli D, Burger M, Hofstaedter F, Hartmann A, Stöhr R, Zwarthoff EC, Sulser T, Wild PJ. Positive fibroblast growth factor receptor 3 immunoreactivity is associated with low-grade non-invasive urothelial bladder cancer.
Oncol Lett. 2015 Nov;10(5):2753-2760.

 

Albers J, Danzer C, Rechsteiner M, Lehmann H, Brandt LP, Hejhal T, Catalano A, Busenhart P, Gonçalves AF, Brandt S, Bode PK, Bode-Lesniewska B, Wild PJ, Frew IJ. A versatile modular vector system for rapid combinatorial mammalian genetics.
J Clin Invest. 2015 Apr;125(4):1603-19.

 

Poyet C, Buser L, Roudnicky F, Detmar M, Hermanns T, Mannhard D, Höhn A, Rüschoff J, Zhong Q, Sulser T, Moch H, Wild PJ (2015) Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer.
J Clin Pathol. 68(10):819-24.

 

Rechsteiner M, Wild P, Kiessling MK, Bohnert A, Zhong Q, Stahel RA, Moch H, and Curioni-Fontecedro A (2015) A novel germline mutation of PDGFR-β might be associated with clinical response of colorectal cancer to regorafenib.
Ann. Onc. 26: 246-248.

 

2014

 

Read More

Jean-Philippe P. Theurillat, Namrata D. Udeshi, Wesley J. Errington, Tanya Svinkina, Sylvan C. Baca, Marius Pop, Peter J. Wild, Mirjam Blattner, Anna C. Groner, Mark A. Rubin, Holger Moch, Gilbert G. Privé, Steven A. Carr, and Levi A. Garraway (2014) Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
Science 346 (6205), 85-89.

 

David N. Church, Ellen Stelloo, Remi A. Nout, Nadejda Valtcheva, Jeroen Depreeuw, Natalja ter Haar, Aurelia Noske, Frederic Amant, Ian P. M. Tomlinson, Peter J. Wild, Diether Lambrechts, Ina M. Jürgenliemk-Schulz, Jan J. Jobsen, Vincent T. H. B. M. Smit, Carien L. Creutzberg, and Tjalling Bosse (2014) Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer.
J Natl Cancer Inst 107: dju402

 

Rechsteiner M, Müller R, Reineke T, Goede J, Bohnert A, Zhong Q, Manz MG, Moch H, Wild PJ, Zimmermann DR, Tinguely M. (2014) Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing.
Exp Hematol Oncol. 3:18. doi: 10.1186/2162-3619-3-18.

 

Ikenberg K, Valtcheva N, Brandt S, Zhong Q, Wong CE, Noske A, Rechsteiner M, Rueschoff JH, Caduff R, Dellas A, Obermann E, Fink D, Fuchs T, Krek W, Moch H, Frew IJ, Wild PJ. (2014) KPNA2 is overexpressed in human and mouse endometrial cancers and promotes cellular proliferation.
J Pathol. doi: 10.1002/path.4390.

 

Kristensen H, Haldrup C, Strand S, Mundbjerg K, Mortensen MM, Thorsen K, Ostenfeld MS, Wild PJ, Arsov C, Goering W, Visakorpi T, Egevad L, Lindberg J, Grönberg H, Høyer S, Borre M, Ørntoft TF, Sørensen KD. (2014) Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
Clin Cancer Res. 20(8):2169-81. doi: 10.1158/1078-0432.CCR-13-2642.

 

Giesen C, Wang HA, Schapiro D, Zivanovic N, Jacobs A, Hattendorf B, Schüffler PJ, Grolimund D, Buhmann JM, Brandt S, Varga Z, Wild PJ, Günther D, Bodenmiller B. (2014) Highly multiplexed imaging of tumor tissues with subcellular resolution by mass cytometry.
Nat Methods. 11(4):417-22. doi: 10.1038/nmeth.2869.

 

Blattner M, Lee DJ, O’Reilly C, Park K, MacDonald TY, Khani F, Turner KR, Chiu YL, Wild PJ, Dolgalev I, Heguy A, Sboner A, Ramazangolu S, Hieronymus H, Sawyers C, Tewari AK, Moch H, Yoon GS, Known YC, Andrén O, Fall K, Demichelis F, Mosquera JM, Robinson BD, Barbieri CE, Rubin MA. (2014) SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Neoplasia. 16(1):14-20.

 

2013

 

Read More

 

Rössle M, Sigg M, Rüschoff JH, Wild PJ, Moch H, Weber A, Rechsteiner MP. (2013) Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
Virchows Arch. 463(5):623-31. doi: 10.1007/s00428-013-1492-3. Epub 2013 Oct 2.

 

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, Moch H, Noske A. (2013) TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Exp Mol Pathol. 95(2):235-41. doi: 10.1016/j.yexmp.2013.08.004.

 

Schüffler PJ, Fuchs TJ, Ong CS, Wild PJ, Rupp NJ, Buhmann JM. (2013) TMARKER: A free software toolkit for histopathological cell counting and staining estimation.
J Pathol Inform. 4(Suppl):S2. doi: 10.4103/2153-3539.109804. Print 2013.

 

2012

 

Read More

Wild P J, Ikenberg K, Fuchs T J, Rechsteiner M, Georgiev S, Fankhauser N, Noske A, Roessle M, Caduff R, Dellas A, Fink D, Moch H, Krek W, Frew I J (2012).
p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumour aggressiveness in humans.
EMBO Mol. Med. 4: 808-24.

 

Meyer S, Fuchs TJ, Bosserhoff A K, Hofstädter F, Pauer A, Roth V, Buhmann J M, Moll I, Anagnostou N, Brandner J M, Ikenberg K, Moch H, Landthaler M, Vogt T, Wild P J (2012).
A Seven-Marker Signature and Clinical Outcome in Malignant Melanoma: A Large-Scale Tissue-Microarray Study With Two Independent Patient Cohorts.
PLoS One 7:e38222.

 

Barbieri C E, Baca S C, Lawrence M S, Demichelis F, Blattner M, Theurillat J P, White T A, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae S S, Boysen G, Auclair D, Onofrio R C, Park K, Kitabayashi N, Macdonald T Y, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter S L, Saksena G, Voet D, Hussain W M, Ramos A H, Winckler W, Redman M C, Ardlie K, Tewari A K, Mosquera J M, Rupp N, Wild P J, Moch H, Morrissey C, Nelson P S, Kantoff P W, Gabriel S B, Golub T R, Meyerson M, Lander E S, Getz G, Rubin M A, Garraway L A (2012).
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer.
Nat. Genet. 44:685-9.

 

Gerstung M, Beisel C, Rechsteiner M, Wild P, Schraml P, Moch H, Beerenwinkel N (2012).
Reliable detection of subclonal single-nucleotide variants in tumour cell populations.
Nat. Commun. 3:811.

 

Fankhauser N, Cima I, Wild P, Krek W (2012).
Identification of a gene expression signature common to distinct cancer pathways.
Cancer Inform. 11:139-46.

 

Gerhardt J, Montani M, Wild P, Beer M, Huber F, Hermanns T, Müntener M, Kristiansen G (2012).
FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer.
Am. J. Pathol. 180:848-61.

 

2011

 

Read More

Von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth A A, Old L, Kristiansen G, van den Broek M, Moch H, Knuth A, Wild P J (2011).
MAGE-C2/CT10 Protein Expression is an Independent Predictor of Recurrence in Prostate Cancer.
PLoS One 6:e21366.

 

Kälin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A, Cerny T, Aebersold R, Krek W, Gillessen S (2011).
Novel prognostic markers in the serum of patients with castration resistant prostate cancer derived from quantitative analysis of the Pten conditional knockout mouse proteome.
Eur. Eurol. 60:1235-43.

 

Mortezavi A, Hermanns T, Seifert H H, Baumgartner M K, Provenzano M, Sulser T, Burger M, Montani M, Ikenberg K, Hofstädter F, Hartmann A, Jaggi R, Moch H, Kristiansen G, Wild P J (2011).
KPNA2 Expression is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy.
Clin. Cancer Res., 17:1111-21.

 

Gluz O, Wild P, Liedtke C, Kates R, Mendrik H, Ehm E, Artinger V, Diallo-Danebrock R, Ting E, Mohrmann S, Poremba C, Harbeck N, Nitz U, Hartmann A, Gaumann A (2011).
Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial.
Breast Cancer Res. Treat., 126:643-51.

 

Cima I, Schiess R, Wild P, Kaelin M, Schüffler P, Lange V, Picotti P, Ossola R, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Zehetner J, Jochum W, Buhmann J, Cerny T, Moch H, Gillessen S, Aebersold R, Krek W (2011).
Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer.
Proc. Natl. Acad. Sci. USA, 108:3342-7.

 

Other Publications

 

big

 

leiner2016_Page_1

 

ercim

 

book

 

book

 

KLS_HD_Maerz_Forschungsblaetter_Wild

 

Monographs

 

book